Effect of particle size and MePEG molecular weight on fixed aqueous layer thickness and surface MePEG of stealth nanoparticles

Chinese Pharmaceutical Journal

Volumn 42, Issue 23, 2007, Pages

  Fang, Chao ^a   Shi, Bin ^b   Hong, Ming Huang ^b   Fan, Li ^a   Pei, Yuan Ying ^b   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Fixed aqueous layer thickness (FALT); Long circulating; MePEG chain density; Nanoparticles; Stealth; Tumor necrosis factor (rHuTNF )

Indexed keywords

MACROGOL; METHOXYPOLYETHYLENEGLYCOL; NANOPARTICLE; POLY(METHOXYPOLYETHYLENEGLYCOL CYANOACRYLATE CO N HEXADECYL CYANOACRYLATE); UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; EMULSION; MOLECULAR WEIGHT; PARTICLE SIZE; PHYSICAL CHEMISTRY; SURFACE PROPERTY; THICKNESS; ZETA POTENTIAL;

EID: 37549020273     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. FANG C, PEI Y Y. Advances in the research of stealth nanoparticles as antitumor drugs carrier[J]. Chin Pharm J ,2004,39(2):89-92.
2. MOCHIMI S M, HUNTER A C, MURRAY J C. Long-circulating and target-specific nanoparticles: theory to practice[J]. Pharmacol Rev,2001,53(2):283-318.
3. MAEDA H, WU J, SAWA T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review[J]. J Controlled Release,2000,65(1-2):271-284.
4. LI Y P, PEI Y Y, ZHOU Z H, et al. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and anti-tumor effects[J]. Biol Pharm Bull,2001,24(6):662-665.
5. BRIGGER I, DUBERNET C, COUVREUR P. Nanoparticles in cancer therapy and diagnosis[J]. Adv Drug Deliv Rev,2002,54(5):631-651.
6. FANG C, SHI B, PEI Y Y. Preparation and stability of recombinant human tumor necrosis factor-α-loaded nanoparticles[J]. Acta Pharm Sin ,2004,39(11):939-943.
7. FANG C, SHI B, PEI Y Y. Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-α-loaded nanoparticles[J]. Acta Pharmacol Sin ,2005,26(2):242-249.
8. TOBIO M, GREF R, SANCHEZ A. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration[J]. Pharm Res,1998,15(2):270-275.
9. LI Y P, PEI Y Y, ZHANG X Y, et al. PEGylated PLGA nanopartilces as protein carriers: synthesis preparation and biodistribution in rats[J]. J Controlled Release,2001,71(2):203-211.
10. SADZUKA Y, HIROTA S. Physical properties and tissue distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes[J]. Adv Drug Del Rev,1997,24(2-3):257-263.
11. BRIGGER I, CHAMINADE P, DESMAELE D, et al. Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology[J]. Pharm Res,2000,17(9):1124-1132.
12. PERACCHIA M T, VAUTHIER C , PASSIRANI C, et al. Complement consumption by poly (ethylene glycol) in different conformations chemically coupled to poly (isobutyl 2-cyanoacrylate) nanoparticles[J]. Life Sci,1997,61(7):749-761.
13. SADZUKA Y, NAKADE A, TSURUDA T, et al. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin[J]. J Controlled Release,2003,91(3):271-280.
14. MOSQUEIRA V C, LEGRAND P, MORGAT J L, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density[J]. Pharm Res,2001,18(10):1411-1419.
15. SADZUKA Y, NAKADE A, HIRAMA R, et al. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome[J]. Int J Pharm,2002,238(1-2) :171-180.